APREA THERAPEUTICS INC (APRE)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$0.79-5.22%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Warn: Primary pillar under pressure — Address Nasdaq listing deficiency: Stock $0.79 vs $1.00 target.
Aprea raised $30 million in a private placement. It beat earnings twice recently. The company works on cancer drugs that fix mutant p53 protein. If it solves Nasdaq listing issues, it can keep operating.
Aprea is still loss-making and faces Nasdaq listing risks. It has no revenue guidance. The stock fell 24.5% from its high. Capital raises dilute shareholders and show cash needs.
The market prices in continued losses and listing risks. There is no clear revenue growth expected. Our view is cautious given the lack of forward guidance and ongoing capital raises.
Breaks if: Private placement raises less than $30 million by 2026-Q1
Breaks if: EPS loss worsens beyond -$0.83 in 2026 or -$0.79 in 2027
Nasdaq delisting due to unresolved deficiency
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The company is currently loss-making and faces high risks, but it operates in a healthcare sector that has favorable trends.
The market seems to expect continued weakness in APRE's financial performance, as it has not performed well compared to peers. Recent earnings beats did not significantly improve market sentiment, indicating that expectations are low.
Management is focused on advancing clinical trials and strengthening the financial position, which shows some positive momentum. However, recent financial performance has been weak, and the company is still loss-making.
The thesis hinges on the company's ability to execute on clinical development and manage its financial health. Key factors include guidance updates and the performance of sector leaders, which could influence APRE's trajectory.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports this improved outlook. There are no new threats impacting the thesis at this time.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
In the next 1 to 3 years, APRE's future will depend on its clinical progress and sector dynamics. Not investment advice.